Phase I/II clinical study of WT1 peptide-based immunotherapy combined with Imatinib for chronic myelogeneous leukemia
Not Applicable
- Conditions
- Chronic myelogeneous leukemia CM
- Registration Number
- JPRN-UMIN000003508
- Lead Sponsor
- Department of Cancer immunotherapy, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Post allogeneic hematopoietic stem cell transplantation 2. There is deep-seated active infection. 3. There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis. 4. Patients who have complications that are considered inappropriate for the trial. 5. Pregnant or lactating woman 6. There is severe psychiatric disorder. 7. There are other active malignancies. 8. Responsible doctors judged the patient inappropriate for the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method